Abstract
A large body of evidence on brain development and ageing has revealed that inflammatory processes profoundly affect brain functions during life span of mammalians, including humans. Activation of innate immune mechanisms leading to pro-inflammatory cytokine up-regulation is involved in devastating and disabling human brain illnesses, as Alzheimers disease (AD), a progressive neurodegenerative disease that causes dementia in the elderly. Emerging data indicate that the cytokine Interleukin (IL)-18, one of the key mediator of inflammation and immune response, has relevance in the physiopathological processes of the brain, by ultimately influencing the integrity of neurons and putatively contributing to AD. In this review, the relationship between specific IL-18-mediated processes and AD neurodegeneration is summarized and clinical studies pointing to a role of the cytokine in the pathology are discussed. Altogether, the presented data indicate that a more complete knowledge of the molecular mechanisms underlying IL-18 implication in neuroinflammatory and neurodegenerative pathways could contribute toward the development of new therapeutic strategies for AD.
Keywords: Interleukin-18, Alzheimer's disease, neuroinflammation, cytokines
Current Pharmaceutical Design
Title: Interleukin-18, From Neuroinflammation to Alzheimers Disease
Volume: 16 Issue: 38
Author(s): Paola Bossu, Antonio Ciaramella, Francesca Salani, Diego Vanni, Ilaria Palladino, Carlo Caltagirone and Giuseppe Scapigliati
Affiliation:
Keywords: Interleukin-18, Alzheimer's disease, neuroinflammation, cytokines
Abstract: A large body of evidence on brain development and ageing has revealed that inflammatory processes profoundly affect brain functions during life span of mammalians, including humans. Activation of innate immune mechanisms leading to pro-inflammatory cytokine up-regulation is involved in devastating and disabling human brain illnesses, as Alzheimers disease (AD), a progressive neurodegenerative disease that causes dementia in the elderly. Emerging data indicate that the cytokine Interleukin (IL)-18, one of the key mediator of inflammation and immune response, has relevance in the physiopathological processes of the brain, by ultimately influencing the integrity of neurons and putatively contributing to AD. In this review, the relationship between specific IL-18-mediated processes and AD neurodegeneration is summarized and clinical studies pointing to a role of the cytokine in the pathology are discussed. Altogether, the presented data indicate that a more complete knowledge of the molecular mechanisms underlying IL-18 implication in neuroinflammatory and neurodegenerative pathways could contribute toward the development of new therapeutic strategies for AD.
Export Options
About this article
Cite this article as:
Bossu Paola, Ciaramella Antonio, Salani Francesca, Vanni Diego, Palladino Ilaria, Caltagirone Carlo and Scapigliati Giuseppe, Interleukin-18, From Neuroinflammation to Alzheimers Disease, Current Pharmaceutical Design 2010; 16 (38) . https://dx.doi.org/10.2174/138161210794519147
DOI https://dx.doi.org/10.2174/138161210794519147 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Protein Tyrosine Nitration: Role in Aging
Current Aging Science Visuospatial Memory in Healthy Elderly, AD and MCI: A Review
Current Aging Science Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates
Current Pediatric Reviews Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice
Current Alzheimer Research Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential
Current Alzheimer Research Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research Neonatal Atlas Templates for the Study of Brain Development Using Magnetic Resonance Images
Current Medical Imaging Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics <i>Crocus Sativus</i> L. (Saffron) in Alzheimer’s Disease Treatment: Bioactive Effects on Cognitive Impairment
Current Neuropharmacology Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire
Current Alzheimer Research Analytical Procedures for Secondary Metabolites Determination: Recent Trends and Future Perspectives
Letters in Drug Design & Discovery